Viracta Therapeutics Stock Beta
| VIRX Stock | USD 0.14 0.01 6.67% |
Viracta Therapeutics fundamentals help investors to digest information that contributes to Viracta Therapeutics' financial success or failures. It also enables traders to predict the movement of Viracta Stock. The fundamental analysis module provides a way to measure Viracta Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Viracta Therapeutics stock.
Viracta | Beta |
Viracta Therapeutics Company Beta Analysis
Viracta Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Viracta Therapeutics Beta | 0.3 |
Most of Viracta Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Viracta Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Viracta Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Viracta Therapeutics is extremely important. It helps to project a fair market value of Viracta Stock properly, considering its historical fundamentals such as Beta. Since Viracta Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Viracta Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Viracta Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Viracta Therapeutics has a Beta of 0.299. This is 65.23% lower than that of the Biotechnology sector and 78.49% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Viracta Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Viracta Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Viracta Therapeutics could also be used in its relative valuation, which is a method of valuing Viracta Therapeutics by comparing valuation metrics of similar companies.Viracta Therapeutics is currently under evaluation in beta category among its peers.
Viracta Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Viracta Therapeutics from analyzing Viracta Therapeutics' financial statements. These drivers represent accounts that assess Viracta Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Viracta Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 29.7M | 647.6K | 116.3M | 55.2M | 22.0M | 20.9M | |
| Enterprise Value | 17.7M | (40.3M) | 18.2M | 43.6M | 35.3M | 33.5M |
Viracta Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Viracta Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Viracta Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Viracta Therapeutics' value.| Shares | State Street Corp | 2024-09-30 | 65.9 K | United Capital Financial Advisers Inc | 2024-09-30 | 43 K | Northern Trust Corp | 2024-09-30 | 38.1 K | Virtu Financial Llc | 2024-06-30 | 30.8 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 30.7 K | Goldman Sachs Group Inc | 2024-09-30 | 27.1 K | Integrys Wealth Advisors Llc | 2024-09-30 | 25 K | Royal Bank Of Canada | 2024-09-30 | 20 K | Wealthtrust Axiom Llc | 2024-09-30 | 16.4 K | Citadel Advisors Llc | 2024-09-30 | 1.5 M | Vanguard Group Inc | 2024-09-30 | 954.5 K |
As returns on the market increase, Viracta Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Viracta Therapeutics is expected to be smaller as well.
Viracta Fundamentals
| Return On Equity | -2.09 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 1.46 M | ||||
| Shares Outstanding | 39.74 M | ||||
| Shares Owned By Insiders | 2.83 % | ||||
| Shares Owned By Institutions | 50.00 % | ||||
| Number Of Shares Shorted | 2.1 M | ||||
| Price To Earning | 2.54 X | ||||
| Price To Book | 3.00 X | ||||
| EBITDA | (46.86 M) | ||||
| Net Income | (51.06 M) | ||||
| Cash And Equivalents | 83.14 M | ||||
| Cash Per Share | 2.21 X | ||||
| Total Debt | 25.56 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 11.96 X | ||||
| Book Value Per Share | 0.33 X | ||||
| Cash Flow From Operations | (39.89 M) | ||||
| Short Ratio | 1.85 X | ||||
| Earnings Per Share | (1.10) X | ||||
| Price To Earnings To Growth | (0.03) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 40 | ||||
| Beta | 0.3 | ||||
| Market Capitalization | 5.68 M | ||||
| Total Asset | 56.69 M | ||||
| Retained Earnings | (265.93 M) | ||||
| Working Capital | 16.59 M | ||||
| Net Asset | 56.69 M |
About Viracta Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Viracta Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viracta Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viracta Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Viracta Stock Analysis
When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.